Figure 4.

Molecular Profile in CT-VT-RT-Treated LNZ308 Cells

(A) Fold change in mRNA expression levels of selected genes identified by RNA-seq, validated at sequential time points post-treatment (36, 72, and 96 hpt) by qPCR. The fold changes in gene expression were significantly higher at 72 and 96 h in VT, CT-VT, and CT-VT-RT when compared to other regimens and with non-significant differences among the VT-containing regimen. The significance values are not depicted to avoid confusing graph outline, unless differing from the above statement. (B) ELISA revealed production of IFN-β along with secretion of pro-inflammatory chemokines CCL5 and CXCL10 measured at 96 hpt. (C) Immunoblot analysis revealed overexpression of SAMD9 (upper panel) in MeV-containing regimen and the induction of TRAIL (middle panel). β-tubulin (lower panel) served as the loading control. (D) Immunoblot analysis showed no change in BATF2 protein expression (upper panel). β-tubulin (lower panel) served as the loading control. (E) Increased effector caspase 3 or 7 activity detected in MeV-containing regimen over respective control, CTL (R/V) regimen. Two-way ANOVA with Tukey’s multiple comparison test in (A) and one-way ANOVA with Dunnett’s multiple comparison test in (B); ns, non-significant; *p < 0.05; **p < 0.01; ***p < 0.001. Data are expressed as mean ± SEM.